An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?